International Journal of Molecular Sciences
November 23, 2022
Alina Wilkowska, Wiesław Jerzy Cubała
17 citations
Treatment-resistant depression is a pleomorphic phenomenon occurring in 30% of patients with depression. The chance to achieve remission decreases with every subsequent episode. It constitutes a significant part of the global disease burden, causes increased morbidity and mortality, and is associated with poor quality of life. It involves multiple difficult-to-treat episodes, with increasing...
Cochrane Database of Systematic Reviews
November 21, 2022
Sivan Schipper, Kabir Nigam, Vanessa Piechotta et al.
4 citations
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the benefits and harms of psychedelic/entactogen‐assisted therapy compared to placebo or active comparators (e.g. antidepressants) for treatment of anxiety, depression, and existential distress in adult palliative care.
Frontiers in Psychiatry
November 17, 2022
Brittany Chubbs, Jay Wang, S. Archer et al.
Ketamine has gained rapid popularity as a treatment option for treatment resistant depression (TRD). Though seen only in limited contexts, ketamine is a potential drug of abuse, addiction and diversion. Clinical ketamine studies to date have not systematically evaluated factors relevant to addiction risk in patients with TRD, but in treating patients with ketamine, risks of potential harms...
Psi Beta Research Journal
November 15, 2022
Eleni Stogianni, Eta Lin
Due to the rise of positive psychology, mindfulness and self-compassion have become part of Western culture, and research on these topics is growing at an exponential rate. Mindfulness and self-compassion help an individual recognize, accept, investigate, and determine the cause of suffering. When people are faced with difficult life struggles such as symptoms of stress, anxiety, and...
Frontiers in Psychiatry
November 14, 2022
Ying Li, Gui-Ping Qu, Huiyan Kong et al.
Background The outbreak of COVID-19 had a widely negative effect on adolescents’ academics, stress, and mental health. At a critical period of cortical development, adolescents’ cognition levels are highly developed, while the ability of emotion control is not developed at the same pace. Faced with negative emotions such as stress and social loneliness caused by COVID-19, adolescents’ “hot”...
Journal of Holistic Nursing
November 9, 2022
Ben Parkinson, Maggie Lawrence, Evelyn McElhinney et al.
17 citations
Purpose: To investigate the experience and outcomes for care partnerships (e.g., spouses, caregivers) who have post-stroke anxiety and/or depression symptoms and used an online mindfulness-based intervention (MBI) together. Design: Explanatory sequential mixed methods case study research. Methods: 5 care partnerships (10 participants) received online MBI, and data was collected in weeks 0, 4,...
Brain, Behavior, & Immunity - Health
November 7, 2022
Brandon Richardson, Andrew J. Macpherson, Francis Rodriguez Bambico
52 citations
Given that available antidepressant pharmacotherapies are not optimally effective, there is a need for alternative treatment options that are rooted in a comprehensive understanding of the illness's pathophysiology. Major depressive disorder (MDD) has been historically attributed to monoamine, i.e., serotonin (5-hydroxytryptamine, 5-HT) imbalance and some brain morphological pathologies that...
Frontiers in Psychology
November 3, 2022
Mindfulness mediates the relationship between positive parenting and aggression, depression, and suicidal ideation: A longitudinal study in middle school students.
New England Journal of Medicine
November 3, 2022
Guy M. Goodwin, Scott T Aaronson, Oscar Alvarez et al.
1,095 citations
Psilocybin is being studied for use in treatment-resistant depression. In this phase 2 double-blind trial, we randomly assigned adults with treatment-resistant depression to receive a single dose of a proprietary, synthetic formulation of psilocybin at a dose of 25 mg, 10 mg, or 1 mg (control), along with psychological support. The primary end point was the change from baseline to week 3 in the...
British medical journal
November 2, 2022
G. Iacobucci
5 citations
single a Researchers investigated the effects of single doses of 25 mg, 10 mg, or 1 mg (control) psilocybin over 12 weeks in 233 patients with treatment resistant depression. They were given the treatment in specialised rooms designed to provide a non-clinical and calming atmosphere where a specially trained therapist was available to provide psychological support. The psychedelic effects of...